Aclarion to Showcase Nociscan Progress at ROTH Conference Amid 2026 Expansion Push
Event summary
- Aclarion will participate in the 38th Annual ROTH Conference on March 22-24, 2026, to discuss its Nociscan platform and 2026 catalysts.
- CEO Brent Ness will hold one-on-one meetings with institutional investors and analysts.
- The company highlights its strong balance sheet with no debt and plans to expand Nociscan adoption in the UK and US.
- Nociscan is a SaaS platform using MR spectroscopy and AI to identify painful discs in chronic low back pain patients.
The big picture
Aclarion's participation in the ROTH Conference underscores its strategic focus on expanding the adoption of its Nociscan platform, a move that aligns with the broader trend of leveraging AI and biomarkers in healthcare diagnostics. The company's strong financial position and targeted market expansion reflect a calculated approach to capitalize on the growing demand for non-invasive diagnostic tools in chronic pain management.
What we're watching
- Adoption Pace
- The pace at which Aclarion can expand Nociscan adoption in the UK and US markets.
- Financial Health
- Whether Aclarion can sustain its strong balance sheet and no-debt position amid expansion efforts.
- Technology Validation
- How the market will respond to the progress and validation of Nociscan's proprietary AI algorithms.